Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label flexible-dose vortioxetine study on emotional functioning in major depressive disorder
2017-004829-33Phase 4Completed
- Sponsor
- Lundbeck
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vortioxetine in major depressive disorder (MDD), sponsored by Lundbeck. Primary endpoint: Change in Oxford Depression Questionnaire total score. Started Jul 2018; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2017-004829-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004829-33.